Endo International (NASDAQ:ENDP) (TSE:ENL) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

Other equities analysts have also recently issued reports about the stock. Canaccord Genuity set a $10.00 price objective on shares of Endo International and gave the stock a “hold” rating in a research note on Monday, August 14th. Guggenheim began coverage on shares of Endo International in a research note on Tuesday. They issued a “neutral” rating and a $8.50 price objective for the company. Cantor Fitzgerald dropped their price objective on shares of Endo International from $9.00 to $7.00 and set a “neutral” rating for the company in a research note on Friday, November 10th. Zacks Investment Research cut shares of Endo International from a “hold” rating to a “sell” rating in a research note on Thursday, October 26th. Finally, Citigroup dropped their price target on shares of Endo International from $9.00 to $7.00 and set a “neutral” rating for the company in a research note on Friday, November 10th. Three equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $11.48.

Shares of Endo International (NASDAQ ENDP) traded up $0.16 during trading hours on Tuesday, hitting $7.88. 5,482,316 shares of the company’s stock were exchanged, compared to its average volume of 7,109,283. Endo International has a 1-year low of $5.77 and a 1-year high of $17.99. The stock has a market cap of $1,674.85, a PE ratio of 1.55, a P/E/G ratio of 2.04 and a beta of 0.59. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 10.78.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings data on Thursday, November 9th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The business had revenue of $786.90 million during the quarter, compared to analysts’ expectations of $794.93 million. During the same period last year, the company posted $1.01 EPS. The business’s revenue was down 11.0% on a year-over-year basis. equities research analysts forecast that Endo International will post 3.67 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in ENDP. Blair William & Co. IL bought a new stake in Endo International during the 2nd quarter valued at about $126,000. Point View Wealth Management Inc. lifted its holdings in Endo International by 16.6% during the 2nd quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock valued at $149,000 after buying an additional 1,900 shares in the last quarter. Riverhead Capital Management LLC lifted its holdings in Endo International by 64.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after buying an additional 5,887 shares in the last quarter. Bank of Hawaii bought a new stake in Endo International during the 2nd quarter valued at about $180,000. Finally, LMR Partners LLP bought a new stake in Endo International during the 3rd quarter valued at about $148,000. 93.17% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Endo International (ENDP) Upgraded at BidaskClub” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/12/endo-international-endp-upgraded-at-bidaskclub.html.

Endo International Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.